
The efficacy and safety profiles of empagliflozin, dapagliflozin, and canagliflozin are generally similar for managing type 2 diabetes, though there are differences in cardiovascular and renal outcomes as well as side-effect profiles.
safety, endocrinology, diabetes management, efficacy, empagliflozin, type 2 diabetes, dapagliflozin, long-term management, canagliflozin, SGLT2 inhibitors
safety, endocrinology, diabetes management, efficacy, empagliflozin, type 2 diabetes, dapagliflozin, long-term management, canagliflozin, SGLT2 inhibitors
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
